Drug Profile
Research programme: Alzheimer's disease, cancer, metabolic disorders and respiratory disease therapeutics - Pfizer/Washington University
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Pfizer
- Developer Washington University School of Medicine
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Alzheimer's disease; Asthma; Cancer; Diabetes mellitus
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Asthma in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA